Dori Thomas-Karyat
Company: Synthis
Job title: Chief Executive Officer
Seminars:
Development of Immune Cell Targeted TGF-ß Therapies to Restore Tumor Clearance in Cancer Patients 4:15 pm
• In cancer patients, TGF-ß mediated immune suppression blocks tumor clearance • Blockade of TGF-ß signaling in immune cells is necessary and sufficient to rescue tumor clearance • At Synthis, we are developing first in class therapeutic platform to selectively and safely block TGF-ß mediated immune suppressionRead more
day: Day Two